Cardiome oxypurinol fails CHF trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryOxypurinol's failure to demonstrate a statistically significant benefit over placebo in congestive heart failure is an "unequivocal negative outcome," the Vancouver firm says Aug. 15. Oxypurinol showed no benefit (p=0.357) for a primary composite endpoint that included NYHA class, global heart failure status and hospitalizations/visits for worsening condition. "In addition, no benefits over placebo were observed in Minnesota CHF Quality of Life index and time to acute clinical events," Cardiome said. The firm plans to "review the data in greater detail prior to making any final decisions about the future of this program"...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.